Objective
The Netherlands proposes to hold a high-level conference on Piority Medicines to address priorities for a research agenda and policy measures to resolve the pharmacological treatment gaps in an expanded Europe. This conference (November 18, 2004), its prep aratory work and follow-up aim to support the G-10 process: innovation for the European pharma industry for the benefit of the patient. Financial back ground for the member states: public spending on pharmaceuticals needs to be targeted in the best interes t of public health. What is the problem? Pharmacological gaps exist in the treatment of patients. For many conditions, pharmaceutical interventions are not available or provide marginal benefits, and many beneficial interventions are burdened with adverse effects. We need a robust methodology to identify these gaps and prioritize them. NL commissioned a study by WHO. WHO will present their methodolgy at the conference. WHO will also present a list of conditions that need further research and policy measures . From basic research ('upstream') to practical and policy incentives. The Dutch Medical Research Council will present preliminary results of an inventory (SSA) of corresponding national research programs in view of establishing an ERANet. Special attentio n for the new member states. The EIB will explore the options for EIB/EIF involvement in the follow-up phase. Stakeholders (industry, doctors, mutualities, ethicists, patients, others) will present position papers and views. Parliamentarians will be invite d. The conference aims to create a shared vision that is politically and scientifically relevant, on the nature of the problems and on possible ways forward. Recommendations will be addressed to policy makers (Commission, member states), the EIB, industry and all other relevant stakeholders. Items for consideration: the selection of priority areas, population groups, delivery mechanisms, types of research, technology platform, FP7, PPP's, SME involvment
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
THE HAGUE
Netherlands
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.